Researchers at the University of Colorado Boulder, CU Anschutz, and Colorado State University have secured federal funding to advance experimental osteoarthritis treatments that aim to regenerate damaged joint tissue. The project, supported by the Advanced Research Projects Agency for Health (ARPA-H), focuses on two regenerative therapies designed to repair cartilage and restore joint function within weeks.
How the New Osteoarthritis Treatments Work
The research team is developing two primary methods to address the degradation of cartilage, which currently affects one in six people over the age of 30 globally. According to the project, these treatments move beyond symptom management:
- Particle-based drug delivery: Researchers developed a patented system that injects an FDA-approved drug into the joint. The system releases the medication periodically over several months to manage the joint environment.
- Biomaterial-based repair: For more severe cases, the team created engineered proteins delivered arthroscopically. This material hardens once inside the joint, creating a scaffold that encourages the body’s own progenitor cells to rebuild damaged cartilage and bone.
Stephanie Bryant, a professor of chemical and biological engineering at CU Boulder and the project’s principal investigator, stated that the team’s goal is to move beyond halting disease progression to actually reversing it.
Progress Under the ARPA-H NITRO Program
This research is part of the Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program, the first program launched by ARPA-H. Dr. Ross Uhrich, an ARPA-H Program Manager, oversees the project, which recently cleared its first phase.
The successful transition to phase two of the program comes with a funding package worth up to $33.5 million. The researchers have also established a company, Renovare Therapeutics Inc., to facilitate the potential commercialization of these technologies.
Results from Animal Studies
In preliminary testing, the injectable treatments showed significant efficacy. According to the research team, animals with joint injuries and osteoarthritis saw their joints return to a healthy state within four to eight weeks.
Regarding the biomaterial repair system, Bryant noted that the treatment led to full regeneration of cartilage and bone defects in animal models. The researchers have also observed regenerative effects in human cells collected from patients who underwent joint replacement surgeries, providing a basis for further development.
What Happens Next for Clinical Trials
While current standard care for advanced osteoarthritis often involves joint replacement surgery or long-term pain management, the Colorado team aims to provide a minimally invasive alternative. Dr. Evalina Burger, professor and chair of the Department of Orthopedics at CU Anschutz, noted that current options leave a gap for patients who require more than conservative care but want to avoid major surgery.
The researchers plan to publish their findings in a peer-reviewed journal later this year. If the development process remains on track, Bryant believes clinical trials could begin in as little as 18 months. The ultimate goal is to provide a one-time, affordable treatment that allows patients to maintain joint health for years, effectively addressing both early-stage injuries and chronic degradation.
Related reading